The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients

European Journal of Internal Medicine

Volumn 21, Issue 4, 2010, Pages 293-296

  Degreef, L E ^a   Opdam, F L ^a   Teepe Twiss, I M ^a   Jukema, J W ^a   Guchelaar, H J ^a   Tamsma, J T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular prevention; LDL cholesterol; Low dose statin; Simvastatin; Statin intolerance

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MALE; MYALGIA; OBSERVATIONAL STUDY; OPEN STUDY; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; BLOOD; MIDDLE AGED;

ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN; TRIGLYCERIDES; HYPOLIPIDEMIC AGENTS;

EID: 77955339223     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.03.015     Document Type: Article

References (21)

1. A. Corsini, E. Windler, and M. Farnier Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol Eur J Cardiovasc Prev Rehabil 16 1 2009 1 9
2. J.J. Brugts, T. Yetgin, S.E. Hoeks, A.M. Gotto, J. Shepherd, and R.G. Westendorp The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials BMJ 338 2009 b2376
3. I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, and R. Cifkova European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 Suppl 2 2007 S1 S113
4. S. Ward, J.M. Lloyd, A. Pandor, M. Holmes, R. Ara, and A. Ryan A systematic review and economic evaluation of statins for the prevention of coronary events Health Technol Assess 11 14 2007 1 160 iii-iv
5. M. Silva, M.L. Matthews, C. Jarvis, N.M. Nolan, P. Belliveau, and M. Malloy Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy Clin Ther 29 2 2007 253 260
6. T.R. Joy, and R.A. Hegele Narrative review: statin-related myopathy Ann Intern Med 150 12 2009 858 868
7. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 40 3 2002 Aug 7 567 572 (Pubitemid 34833176)
8. R. Arora, M. Liebo, and F. Maldonado Statin-induced myopathy: the two faces of Janus J Cardiovasc Pharmacol Ther 11 2 2006 Jun 105 112
9. A.N. Baer, and R.L. Wortmann Myotoxicity associated with lipid-lowering drugs Curr Opin Rheumatol 19 1 2007 67 73
10. C.R. Harper, and T.A. Jacobson The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis Curr Opin Lipidol 18 4 2007 401 408
11. R.M. Conroy, K. Pyorala, A.P. Fitzgerald, S. Sans, A. Menotti, and B.G. De Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 11 2003 987 1003
12. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, and C. Pollicino Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
13. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
14. M.S. Matalka, M.C. Ravnan, and P.C. Deedwania Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS) Am Heart J 144 4 2002 674 677
15. J.C. Ferrer-Garcia, J. Perez-Silvestre, I. Martinez-Mir, and A. Herrera-Ballester Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia Acta Diabetol 43 3 2006 75 78
16. M. Gadarla, A.K. Kearns, and P.D. Thompson Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins Am J Cardiol 101 12 2008 1747 1748
17. J.F. Ruisinger, J.M. Backes, C.A. Gibson, and P.M. Moriarty Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance Am J Cardiol 103 3 2009 393 394
18. J.M. Backes, P.M. Moriarty, J.F. Ruisinger, and C.A. Gibson Effects of once weekly rosuvastatin among patients with a prior statin intolerance Am J Cardiol 100 3 2007 554 555
19. B.D. Mackie, S. Satija, C. Nell, J. Miller III, and L.S. Sperling Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy Am J Cardiol 99 2 2007 291
20. M.J. Mol, D.W. Erkelens, J.A. Leuven, J.A. Schouten, and A.F. Stalenhoef Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia Lancet 2 8513 1986 936 939
21. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, and F. Matsuda SLCO1B1 variants and statin-induced myopathy - a genowide study N Engl J Med 359 8 2008 789 799